ask why
Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

New medicines: EU opinions and licences, US approvals

CHMP opinions and European Commission licences from the European Medicines Agency, and new medicines approved by the US FDA. Shown in the regulator's own words, with a link to the source; checked every two hours. This is regulatory news, not medical advice, and not sponsored.

November 2026

US · FDA approval, new medicine

Neladalkib (Nelkarmi)

To treat locally advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer after certain previous therapies

Approved 17 Nov 2026
US · FDA approval, new medicine

Giredestrant (Wilserdly)

To treat adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, estrogen receptor 1-mutated locally advanced or metastatic breast cancer whose disease has recurred during or after endocrine-based adjuvant therapy, or has progressed on at least one endocrine-based regimen in the metastatic setting

Randomised trials of this medicine for this use, found by Y in PubMed (the regulator's assessment may rest on other studies too):

In ER+/HER2− advanced breast cancer after a CDK4/6 inhibitor, giredestrant plus everolimus improved PFS vs standard endocrine therapy plus everolimus: median 10.0 vs 5.5 months in ESR1-mutated (HR 0.38) and 8.8 vs 5.5 overall (HR 0.56); adverse events similar. RCT · phase 3 · n = 373 · N Engl J Med · 2026

1 trial is being summarised and will appear here shortly.

Approved 16 Nov 2026
US · FDA approval, new medicine

Gefurulimab-gaks (Klygefa)

To treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis

Randomised trials of this medicine for this use, found by Y in PubMed (the regulator's assessment may rest on other studies too):

In 260 adults with AChR antibody-positive generalised myasthenia gravis, weekly subcutaneous gefurulimab improved MG-ADL score at 26 weeks vs placebo (−4.2 vs −2.6; difference −1.6, P<.001); QMG also improved; adverse events were similar. RCT · phase 3 · n = 260 · JAMA Neurol · 2026

Approved 13 Nov 2026
US · FDA approval, new medicine

Pimicotinib (Pimjetmi)

To treat adults with symptomatic tenosynovial giant cell tumors in whom surgical resection may cause worsening functional limitation or severe morbidity

Randomised trials of this medicine for this use, found by Y in PubMed (the regulator's assessment may rest on other studies too):

In 94 adults with unresectable, symptomatic tenosynovial giant cell tumour, pimicotinib gave a week-25 objective response rate of 54% vs 3% with placebo (difference 51%). Grade 3–4 creatine phosphokinase rise occurred in 13%; mostly mild adverse events. RCT · phase 3 · n = 94 · Lancet · 2026

Approved 13 Nov 2026
US · FDA approval, new medicine

Asundexian (Sunharbo)

To reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack

Approved 9 Nov 2026

October 2026

US · FDA approval, new medicine

Bepirovirsen (Hibsago)

To treat chronic hepatitis B virus infection in certain adults without cirrhosis, in combination with existing antiviral therapy

Approved 20 Oct 2026
US · FDA approval, new medicine

Pritelivir (Hovilpri)

To treat adults with weakened immune systems who have mucocutaneous lesions caused by herpes simplex virus infection and have not responded to other therapies

Approved 9 Oct 2026

September 2026

US · FDA approval, new medicine

Tavapadon (Juvmo)

To treat Parkinson’s disease in adults

Approved 25 Sept 2026
US · FDA approval, new medicine

Zilurgisertib (Atebrioz)

To reduce the volume of total new heterotopic ossification in adults and pediatric patients 12 years and older with fibrodysplasia ossificans progressiva

Approved 25 Sept 2026
US · FDA approval, new medicine

Insulin efsitora alfa-gobe (Onswik)

To improve glycemic control in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise

Randomised trials of this medicine for this use, found by Y in PubMed (the regulator's assessment may rest on other studies too):

2 trials are being summarised and will appear here shortly.

Approved 23 Sept 2026
US · FDA approval, new medicine

Lirafugratinib (Lyrfigtu)

To adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 gene fusion or other rearrangement

Approved 23 Sept 2026
US · FDA approval, new medicine

Apitegromab-mstn (Isembyld)

To treat spinal muscular atrophy in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatment

Approved 11 Sept 2026
US · FDA approval, new medicine

Floretyrosine F 18 (Pixclara)

To use with positron emission tomography to differentiate recurrent or progressive glioma from treatment-related change in conjunction with other diagnostic evaluations

Approved 11 Sept 2026
US · FDA approval, new medicine

Camizestrant (Etcamah)

To treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy

Approved 4 Sept 2026

August 2026

US · FDA approval, new medicine

Garetosmab-grts (Pasatru)

To reduce new heterotopic ossification and clinician-assessed disease flare-ups in adults with fibrodysplasia ossificans progressiva

Approved 19 Aug 2026
US · FDA approval, new medicine

Florquinitau F 18 (Tauklarify)

To be used for positron emission tomography of the brain in adults with cognitive impairment who are being evaluated for Alzheimer disease to identify patients with tau neurofibrillary tangle pathology

Approved 13 Aug 2026
US · FDA approval, new medicine

Iberdomide (Zenbexus)

To be used in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent

Approved 13 Aug 2026

July 2026

US · FDA approval, new medicine

Zidesamtinib (Jideytro)

To treat adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer after receiving a ROS1 kinase inhibitor

Approved 22 Jul 2026
US · FDA approval, new medicine

Gedatolisib (Revtorpyk)

In combination with fulvestran, to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting

Approved 14 Jul 2026
US · FDA approval, new medicine

Atacicept-vymj (Trutakna)

To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression

Approved 7 Jul 2026

June 2026

US · FDA approval, new medicine

Tebipenem pivoxil (Utebzi)

To treat complicated urinary tract infections, including pyelonephritis, caused by several susceptible microorganisms in adults who have limited or no alternative oral treatment options

Approved 17 Jun 2026
US · FDA approval, new medicine

Gadoquatrane (Ambelvist)

To detect and visualize lesions with abnormal vascularity, in conjunction with MRI

Approved 12 Jun 2026

May 2026

US · FDA approval, new medicine

Cefepime and zidebactam (Zaynich)

To treat complicated urinary tract infections, including pyelonephritis, caused by designated susceptible microorganisms

Approved 29 May 2026
US · FDA approval, new medicine

Sonrotoclax (Beqalzi)

To treat adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase inhibitor

Approved 13 May 2026
US · FDA approval, new medicine

Vepdegestrant (Veppanu)

To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy

Approved 1 May 2026

April 2026

US · FDA approval, new medicine

Doravirine and islatravir (Idvynso)

To treat HIV-1 infection (as a complete regimen) in adults to replace the current antiretroviral regimen in those who are virologically-suppressed on a stable antiretroviral regimen with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine

Approved 20 Apr 2026
US · FDA approval, new medicine

Orforglipron (Foundayo)

To reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity

Approved 1 Apr 2026

March 2026

US · FDA approval, new medicine

Relacorilant (Lifyorli)

To treat platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after one to three prior systemic treatment regimens, at least one of which included bevacizumab

Approved 25 Mar 2026
US · FDA approval, new medicine

Tividenofusp alfa-eknm (Avlayah)

To treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II)

Approved 24 Mar 2026

February 2026

US · FDA approval, new medicine

Pegzilarginase-nbln (Loargys)

To treat hyperarginemia in adults and pediatric patients two years and older with Arginase 1 Deficiency, in conjunction with dietary protein restriction

Approved 23 Feb 2026
US · FDA approval, new medicine

Milsaperidone (Bysanti)

To treat schizophrenia and to treat manic or mixed episodes associated with bipolar I disorder

Approved 20 Feb 2026

January 2026

December 2025

US · FDA approval, new medicine

Narsoplimab-wuug (Yartemlea)

To treat hematopoietic stem cell transplant-associated thrombotic microangiopathy

Approved 23 Dec 2025
US · FDA approval, new medicine

Lerodalcibep-liga (Lerochol)

To reduce low-density lipoprotein cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, as an adjunct to diet and exercise

Approved 12 Dec 2025

November 2025

US · FDA approval, new medicine

Sevabertinib (Hyrnuo)

To treat locally advanced or metastatic non-squamous non-small cell lung cancer with tumors that have activating HER2 tyrosine kinase domain activating mutations in patients who received a systemic therapy

Approved 19 Nov 2025
US · FDA approval, new medicine

Ziftomenib (Komzifti)

To treat adults with relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 mutation who have no satisfactory alternative treatment options

Approved 13 Nov 2025
US · FDA approval, new medicine

Doxecitine and doxribtimine (Kygevvi)

To treat thymidine kinase 2 deficiency in patients who start to show symptoms when they are 12 years old or younger

Approved 3 Nov 2025

October 2025

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.